Clinical Scorecard: Ocular Risks of Glucagon-Like Peptide-1 Agonists

At a Glance

Key Highlights

• GLP-1s linked to worsening diabetic retinopathy
• Associated with nonarteritic anterior ischemic optic neuropathy
• Recent links to neovascular age-related macular degeneration
• 6% of adults in the US using GLP-1s as of 2024
• Clinical recommendations provided for optometric care

Guideline-Based Recommendations

Diagnosis

• Monitor for signs of diabetic retinopathy in patients on GLP-1s
• Assess risk for NAION and neovascular AMD

Management

• Provide guidance on ocular health monitoring for patients using GLP-1s
• Educate patients about potential ocular risks

Monitoring & Follow-up

• Regular eye examinations for patients on GLP-1 therapy
• Evaluate changes in vision and ocular health

Risks

• Increased risk of diabetic retinopathy progression
• Potential for NAION and neovascular AMD

Patient & Prescribing Data

Adults prescribed GLP-1 receptor agonists for diabetes and/or weight loss

Awareness of ocular risks is crucial for patient management

Clinical Best Practices

• Incorporate ocular health assessments in routine care for GLP-1 users
• Stay updated on emerging research regarding GLP-1s and ocular risks
• Collaborate with healthcare providers for comprehensive patient management

References

• Glucagon-like Peptide-1 Receptor Agonists and Ocular Health: Guidance for Optometric Practice
• Diabetic Retinopathy and Glucagon-Like Peptide-1 Agonists